证券代码：002022 证券简称：科华生物 编号：2020002 | --- | --- | --- | --- | |---------------------------|----------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 □ | | 媒体采访 | | 特定对象来 | □ 分析师会议 □ | √ | 业绩说明会 | | 访目的 | □ 新闻发布会 | □ | 现场参观 | | | □ 其他（请文字说明） | | | | 来访者单位名称 及人员姓名 | 通过"全景·路演天下"（ 司 2020 | | http://rs.p5w.net ）参加公 ...

证券代码：002022 证券简称：*ST 科华 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 投资者关系活动记录表 编号：2022001 | --- | --- | --- | |-----------------------|---------------------------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 类别 | □ 特定对象调研 □ 媒体采访 | □ 分析师会议 √ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | □ 通过全景网"投资者关系互动平台"（ | http://ir.p5w.net | | 人员姓名 | 加公司 2021 | 年度网上业绩说明会的投资者 | | 时间 | 2022 年 5 月 25 日 | (周三) 下午 15:00-17:00 | | 地点 | 公司通过全景网"投资者关系互动平台" ...

Financial Performance - The company's operating revenue for 2021 was CNY 4,268,011,808.72, representing a 2.71% increase compared to CNY 4,155,428,846.74 in 2020[20] - The net profit attributable to shareholders for 2021 was CNY 721,016,662.06, a 6.76% increase from CNY 675,356,413.28 in 2020[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 704,501,000.58, up 6.92% from CNY 658,928,540.60 in 2020[20] - Basic earnings per share for 2021 were CNY 1.4026, an increase of 5.10% from CNY 1.3345 in 2020[20] - The diluted earnings per share for 2021 were CNY 1.3641, a 3.54% increase from CNY 1.3175 in 2020[20] - The weighted average return on equity decreased to 20.87% from 24.76% in 2020, a decline of 3.89%[20] - Total assets at the end of 2021 were CNY 5,276,579,515.63, down 11.72% from CNY 5,977,153,474.43 at the end of 2020[20] - The net cash flow from operating activities decreased by 43.29% to CNY 775,342,174.21 from CNY 1,367,198,250.32 in 2020[20] - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[124] - The company reported a net profit of 300 million RMB, reflecting a 20% increase from the previous year[124] Market and Product Development - The company’s main business includes the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, focusing on molecular, biochemical, and immunodiagnostics[34] - The global in vitro diagnostic market exceeded $111.7 billion in 2021, with a projected CAGR of 6.1% from 2017 to 2024, indicating strong growth potential in the industry[32] - The company has over 200 diagnostic reagents and instruments, with more than 80 products certified by the EU CE mark, and has exported products to over 30 countries and regions[34] - The company launched 21 reagent products and 2 instrument products that received medical device registration certificates during the reporting period, enhancing its product portfolio[44] - The Polaris ic6000 product was successfully launched, designed for large laboratories, contributing to the company's innovation in automated biochemical and immunological analysis systems[42] - The company aims to launch three new products in the next quarter, which are anticipated to contribute an additional 100 million RMB in revenue[126] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[125] Research and Development - The company has over 100 ongoing research projects and has obtained 260 CFDA registration certificates and more than 50 invention patents[38] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[119] - Investment in R&D for new technologies increased by 25%, totaling 200 million RMB, focusing on immunological and molecular diagnostics[124] - The company will continue to invest in R&D, particularly in molecular and immunological fields, to develop new products and improve existing ones[97] Challenges and Risks - The company faces risks related to the ongoing COVID-19 pandemic, which may impact sales of diagnostic products[98] - Regulatory changes in the in vitro diagnostic industry pose a risk to the company's operations and compliance[99] - The company faces increasing challenges in the in vitro diagnostic industry due to healthcare cost control measures, which may accelerate industry concentration and require manufacturers to strengthen their marketing capabilities[101] - The company is currently involved in a significant arbitration case, with the Shanghai International Economic and Trade Arbitration Commission having formed a tribunal, but no ruling has been made yet, making the impact on profits uncertain[102] - The company's stock has been placed under delisting risk warning due to management violations at its subsidiaries, leading to an "unable to express opinion" audit report for the 2021 fiscal year[102] Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and various committees to ensure compliance with laws and regulations[107] - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management to ensure the achievement of strategic goals[109] - The company has committed to improving its information disclosure practices, ensuring timely and accurate communication with investors[110] - The company maintains complete independence from its major shareholders in terms of business operations, personnel, assets, institutions, and finance[111] - The company has established independent departments for various functions, including sales, R&D, procurement, and finance, ensuring operational independence[112] Employee and Operational Management - The total number of employees at the end of the reporting period was 1,485, with 926 in the parent company and 559 in major subsidiaries[137] - The company has a training plan that includes diverse training programs for different employee levels, aimed at enhancing organizational performance[140] - The company has established a performance-oriented compensation system that aligns employee contributions with organizational goals[139] - The company’s internal control and compliance management received positive feedback from the audit committee, indicating effective governance[136] Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 0.65 per 10 shares (including tax) to all shareholders[6] - The total distributable profit for the period was 759,082,903.41 CNY, with the cash dividend representing 100% of the profit distribution[144] - The company did not propose any stock dividends or capital reserve transfers during the reporting period[146] Financial Management and Investments - The company has established a new supply chain management structure to optimize processes and reduce costs, enhancing operational efficiency[46] - The company reported a significant decrease in investment amounting to CNY 7.14 million, a decline of 71.27% compared to the previous year's CNY 24.85 million[77] - The company raised a total of CNY 738 million through the issuance of convertible bonds, with a net amount of CNY 718.53 million after deducting issuance costs[85] Social Responsibility - A 22-member volunteer team was formed to assist in COVID-19 testing efforts, demonstrating the company's commitment to social responsibility[166]

Financial Performance - The company's operating revenue for 2020 was CNY 4,155,428,846.74, representing a 72.11% increase compared to CNY 2,414,471,289.30 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 675,356,413.28, a significant increase of 233.55% from CNY 202,475,418.80 in the previous year[16] - The net cash flow from operating activities reached CNY 1,367,198,250.32, marking a 449.36% increase compared to CNY 248,872,034.68 in 2019[16] - The basic earnings per share for 2020 was CNY 1.3345, up 238.10% from CNY 0.3947 in 2019[16] - The total assets at the end of 2020 amounted to CNY 5,977,153,474.43, reflecting a 61.33% increase from CNY 3,704,842,430.09 at the end of 2019[16] - The net profit after deducting non-recurring gains and losses for 2020 was CNY 658,928,540.60, which is a 258.44% increase from CNY 183,830,664.07 in 2019[16] - The company reported a weighted average return on equity of 24.76%, an increase of 15.85 percentage points from 8.91% in 2019[16] - The revenue from self-produced products amounted to ¥2,681,480,912.21, a significant increase of 145.67% from ¥1,091,489,519.78 in the previous year[66] - The international revenue surged by 283.88%, reaching ¥851,395,974.97, compared to ¥221,789,113.38 in 2019[66] - The company reported a cash dividend of ¥102,871,448.60 for the fiscal year 2020, which represents 15.23% of the net profit attributable to ordinary shareholders[128] Market Position and Strategy - The company has a total of over 260 approved diagnostic reagents and instruments, with 80 products certified by the EU CE mark[25] - The company focuses on three main diagnostic areas: immunodiagnostics, biochemical diagnostics, and molecular diagnostics, enhancing its product portfolio[25] - The company aims to become a pillar in the IVD field, emphasizing customer-centric innovation and collaboration[25] - The company has established a network of over 12,000 terminal hospitals and more than 500 high-barrier disease control centers and blood centers across 30 provinces and regions in China[29] - The company has seen a notable increase in its share of the domestic IVD market due to the shift towards domestic products amid import substitution trends[42] - The company is positioned to benefit from national policies supporting the biotechnology industry, which is recognized as a strategic emerging industry[39] - The company aims to leverage its comprehensive advantages in the in vitro diagnostic industry to drive innovation and develop new products that meet market demands[104] Research and Development - The company has established a postdoctoral research station and several technology innovation centers, reinforcing its commitment to R&D[25] - The company has over 100 ongoing research projects and has obtained 260 CFDA registration certificates and over 50 invention patents[46] - The company has made significant investments in the R&D of intelligent medical devices, particularly in its subsidiary Xi'an Tianlong[45] - Research and development expenses rose by 123.76% to CNY 146.93 million in 2020, compared to CNY 65.66 million in 2019[76] - In 2021, the company plans to enhance its R&D capabilities by increasing investment and recruiting high-tech talent, focusing on molecular and immunological fields[106] Product Development and Innovation - The company sold over 13,500 nucleic acid extraction devices and 9.1 million nucleic acid extraction reagents during the reporting period, significantly boosting sales performance[56] - The Polaris series products, including fully automated biochemical and immunoassay systems, have been launched, with the Polaris C2000 achieving a testing speed of 2,000 tests per hour[57] - The company has developed 35 new biochemical diagnostic products, 44 new chemiluminescence products, and 23 new molecular diagnostic products, all at various stages of development[59] - The company actively developed COVID-19 testing solutions, contributing to its significant sales growth during the pandemic[56] - The company has successfully registered its AIDS diagnostic products in over 30 countries, contributing significantly to global AIDS prevention efforts[187] Corporate Governance and Compliance - The company has established a quality assurance department and a regulatory affairs department to ensure timely registration of products in domestic and international markets[116] - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profit to be distributed as cash dividends, with a cumulative distribution of at least 30% over three years[123] - The company has established a comprehensive quality management system in compliance with GMP, ISO13485, and other relevant standards, ensuring rigorous quality control throughout the production process[184] - The company has maintained compliance with environmental protection laws and has not faced any significant penalties during the reporting period[190] - The company has received the AAA credit rating for contract compliance from Shanghai for several consecutive years, indicating strong financial stability and debt repayment capability[178] Social Responsibility and Community Engagement - The company actively engages in corporate social responsibility, balancing profit maximization with contributions to sustainable development and social welfare[1] - The company has actively participated in the fight against COVID-19 by donating 10,000 nucleic acid test kits to Wuhan hospitals and providing additional support to other medical institutions[188] - The company has a strong commitment to social responsibility, actively engaging in blood donation activities and supporting public health initiatives[187] Risks and Challenges - The company recognizes the ongoing risks posed by the COVID-19 pandemic, which may affect the sales of routine diagnostic products[113] - Regulatory changes in the in vitro diagnostic industry pose potential risks, necessitating close monitoring and adjustments to comply with new policies[114] - The company faces high risks in new product development due to the complex and lengthy process, which typically takes 3-5 years from project initiation to market launch[115] - The company has faced challenges in timely registration of innovative products, which could adversely affect its business plans[116] Shareholder Engagement and Financial Management - The company held 2 shareholder meetings in 2020, utilizing online voting to facilitate participation from public shareholders, especially small and medium-sized shareholders[174] - The board approved the profit distribution plan, which is subject to shareholder approval at the annual general meeting[130] - The company has not proposed any stock dividends or capital reserve transfers for the fiscal year 2020[130] - The company has not proposed any share buybacks during the reporting period[129]

上海科华生物工程股份有限公司 2019 年第三季度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人胡勇敏、主管会计工作负责人罗芳及会计机构负责人(会计主管人员)王强声明：保证季度 报告中财务报表的真实、准确、完整。 上海科华生物工程股份有限公司 2019 年第三季度报告 2019 年 10 月 1 上海科华生物工程股份有限公司 2019 年第三季度报告全文 第一节 重要提示 第二节 公司基本情况 一、主要会计数据和财务指标 报告期内，公司紧密围绕既定的发展战略目标，专注主营业务，聚焦优势领域，重视技术创新和产品研发，丰富公司产 品线，坚持"以产品为核心，以市场为导向"的发展观，持续内部挖潜，优化资源配置。年初至报告期末，公司实现营业总 收入 176,703 万元，同比增长 20.03%；实现归属于母公司所有者的净利润 20,831 万元，同比增长 3.75%。经营活动现金流 量净额 23,333 万元，同比增长 902.92%。由于并购投资活 ...

上海科华生物工程股份有限公司 2018 年半年度报告全文 上海科华生物工程股份有限公司 2018 年半年度报告 2018 年 08 月 1 | 第一节 | 重要提示、目录和释义 | | 3 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 5 | | 第三节 | 公司业务概要 | | 8 | | 第四节 | 经营情况讨论与分析 | | 11 | | 第五节 | 重要事项 | | 23 | | 第六节 | 股份变动及股东情况 | | 30 | | 第七节 | 优先股相关情况 | | 36 | | 第八节 | 董事、监事、高级管理人员情况 | | 37 | | 第九节 | 公司债相关情况 | | 38 | | 第十节 | 财务报告 | | 39 | | 第十一节 | 备查文件目录 | | 123 | 上海科华生物工程股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人胡勇敏、主管会 ...

Financial Performance - The company's operating revenue for 2017 was ¥1,594,116,212.29, representing a 14.14% increase compared to ¥1,396,672,088.94 in 2016[22]. - The net profit attributable to shareholders for 2017 was ¥217,759,949.26, a decrease of 6.30% from ¥232,400,489.43 in 2016[22]. - The net cash flow from operating activities decreased by 53.52% to ¥130,713,194.36 in 2017 from ¥281,252,696.43 in 2016[22]. - The total assets at the end of 2017 were ¥2,715,600,593.39, an increase of 16.89% from ¥2,323,194,784.42 at the end of 2016[22]. - The basic earnings per share for 2017 was ¥0.4248, down 6.31% from ¥0.4534 in 2016[22]. - The weighted average return on net assets for 2017 was 11.33%, a decrease from 13.20% in 2016[22]. - The company achieved total revenue of 1,594.12 million yuan, a year-on-year increase of 14.14%[47]. - The net profit attributable to the parent company was 217.76 million yuan, a year-on-year decrease of 6.30%[47]. - The total assets reached 2,715.60 million yuan, an increase of 16.89% compared to the previous year[47]. Dividend Distribution - The company plans to distribute a cash dividend of 0.65 RMB per 10 shares to all shareholders, based on a total of 512,569,193 shares[10]. - The cash dividend represents 15.30% of the net profit attributable to the company's ordinary shareholders, which was 217,759,949.26 yuan for 2017[100]. - The total number of shares for the dividend distribution is based on 512,569,193 shares[101]. - The company did not issue any bonus shares or increase capital from reserves for the year 2017[104]. - The cash dividend payout ratio for 2016 was 29.77%, with a total distribution of 69,196,841.06 yuan[100]. - The cash dividend payout ratio for 2015 was 29.20%, with a total distribution of 61,508,303.16 yuan[100]. - The company reported a total distributable profit of 549,047,347.33 yuan for the year 2017[101]. - The company has committed to not issuing bonus shares or increasing capital from reserves in the current dividend plan[104]. - The company has maintained a consistent dividend policy over the past three years, with cash dividends paid each year[100]. - The company’s profit distribution plan for 2017 is subject to approval at the annual general meeting[104]. Market and Industry Insights - The in-vitro diagnostics industry is experiencing rapid growth, with increasing competition from both domestic and international companies, particularly in high-end markets[7]. - The in-vitro diagnostics market in China is seen as having significant growth potential due to the large population and improving healthcare policies[7]. - The global IVD market reached $49.4 billion in 2016 and is projected to grow at a CAGR of 5.9% to $69.6 billion by 2022, indicating significant growth potential for the industry[36]. - The domestic IVD market is expected to grow rapidly due to increasing demand driven by an aging population and rising health awareness among residents[36]. - The IVD industry is witnessing a shift towards product upgrades and innovations in business models, driven by advancements in diagnostic technology[37]. Research and Development - The company emphasizes the importance of R&D and innovation, facing risks associated with the lengthy and complex process of new product development, which can take 3-5 years[8]. - The company aims to balance innovation with risk management in its R&D efforts to minimize the potential for project failures[8]. - The company has established a comprehensive R&D platform for clinical in vitro diagnostic reagents and automated diagnostic instruments[32]. - The R&D team has over 400 professionals, focusing on continuous technological and product innovation[44]. - The company plans to enhance its product line and maintain technological leadership by accelerating new product development and registration, particularly in molecular and POCT fields[90]. - The company is committed to enhancing core competitiveness through increased investment in vocational training and customized training programs[177]. Acquisitions and Strategic Initiatives - The company has undertaken several acquisitions, which require careful integration to mitigate risks related to cultural and operational differences[10]. - The company has acquired 60% of Shanghai Merieux Biological Engineering Co., increasing its stake from 40% to 100%, which will enhance its operational capabilities[41]. - The company acquired 51% of Xi'an Shenkai, 55% of Guangdong Xinyou, and 60% of Shanghai Merieux, increasing its consolidated reporting scope[63]. - A strategic alliance was formed with Biokit S.A. for the distribution of automated chemiluminescence products in China[51]. - The company is actively expanding its international market presence, leveraging established sales networks and customer resources from its acquisitions[45]. Operational Challenges and Risks - The company acknowledges the risk of talent loss in its R&D department due to increasing market competition and plans to focus on attracting and retaining high-quality professionals[9]. - The company is aware of the risks associated with raw material procurement, as specific materials are sourced from limited suppliers, which could impact production if supply issues arise[9]. - The company has reported a significant increase in accounts receivable due to rising revenues and the consolidation of subsidiaries[41]. - Cash flow from operating activities showed a significant discrepancy compared to net profit for the year, primarily due to increased accounts receivable and higher operational costs[72]. Corporate Governance and Compliance - The company has established a sound governance structure to protect investor rights, focusing on transparency and fairness[134]. - The company has implemented a second stock option incentive plan, approved by the board on February 28, 2018[117]. - The company has not faced any penalties or rectification situations during the reporting period[115]. - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates[107]. - The company has maintained effective internal controls related to financial statements as of December 31, 2017, in accordance with the Basic Norms for Enterprise Internal Control issued by the Ministry of Finance and other five ministries[198]. Employee and Workforce Management - The company has a workforce of nearly 1,000 employees and emphasizes the protection of employee rights and interests[136]. - The company has achieved a 100% coverage rate for new employee onboarding training[139]. - The company organizes nearly 20 training sessions annually to enhance employee skills and management levels[139]. - The company emphasizes a compensation policy that aligns employee responsibilities with benefits, aiming for internal equity and market competitiveness[176]. - The company has a total of 120 employees with a master's degree or above, accounting for about 11.3% of the workforce[175]. Environmental and Social Responsibility - The company has implemented a strict hazardous waste management system, ensuring safe disposal and compliance with environmental regulations[143]. - The company is actively pursuing "clean production" certification and aims to maximize resource utilization and minimize waste through various sustainability initiatives[143]. - The company has committed to energy conservation and pollution reduction, aligning with the green development theme and promoting a low-carbon economy[142]. - The company strictly adheres to all legal and regulatory requirements regarding environmental protection[147].